Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: TobagoJack who wrote (180582)	11/21/2021 10:17:28 PM
From: Pogeu Mahone	Read Replies (1) \| Respond to of 218598

Anyone still think this virus is going to fade quickly? The sheer range of species involved staggers Dr Han. “I never imagined that we would ever see a virus with such a high cross-species infection potential,” she says. “It appears that there are at least an order of magnitude more species that are susceptible to SARS-CoV-2 infection than any other zoonotic virus I can think of.”

To: TobagoJack who wrote (180582)	11/22/2021 7:54:46 AM
From: Julius Wong	Read Replies (1) \| Respond to of 218598

Pfizer-BioNTech's COVID-19 vaccine shows 100% efficacy in long-term analysis in adolescents Nov. 22, 2021 7:06 AM ET Pfizer Inc. (PFE), BNTX By: Mamta Mayani, SA News Editor 17 Comments carmengabriela/iStock Editorial via Getty Images Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announce topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15 years of age. The updated findings from Phase 3 trial show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-µg per dose) was 100% (95% [CI, 87.5, 100.0]) effective against COVID-19, measured seven days through over four months after the second dose. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least 6 months of safety follow-up after the second dose. These longer-term follow-up data will form the basis for a planned supplemental Biologics License Application (sBLA) to be submitted to the FDA to expand approval of the vaccine for use in individuals 12 years and older. The vaccine is currently available for individuals 12 through 15 years of age under Emergency Use Authorization, granted by the FDA in May 2021. Recently, CDC endorsed Pfizer-BioNTech's COVID-19 boosters to all adults 18 years of age and older.